Sensus Healthcare, Inc.
NASDAQ:SRTSMedical - Devices
+$0.09 today
- Market cap
- $53.01M
- Beta
- 1.09
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.47
Volume 0.08M
Average 0.06M
SRTS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sensus Healthcare, Inc.NASDAQ: SRTS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $1.59M fell 39.0% year over year, behind the +14.7% change in trailing-twelve-month research & development. Sequentially, it fell 15.5% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.
Context
- Research & development amounted to 28.3% of revenue in FY2025, up 18.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -39.0% toward the trailing-twelve-month pace of +14.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.78M USD
- Year-over-year change
- +84.5%
- 4-year CAGR
- +22.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.78M | +84.5% |
| FY2024 | 2024-12-31 | 4.22M | +14.6% |
| FY2023 | 2023-12-31 | 3.68M | +6.3% |
| FY2022 | 2022-12-31 | 3.46M | +0.7% |
| FY2021 | 2021-12-31 | 3.44M | — |
Research & Development vs competitors
How SRTS compares with its peers on the latest reported figures
- SRTS's LTM Mar 2026 research & development of $6.76M is the lowest of the 6 companies compared; the peer median is $20.13M.
- Its year-over-year change of +14.7% is the 2nd highest of 6, against a peer median of -12.3%.
- Research & development amounts to 30.0% of revenue for SRTS, versus a peer median of 62.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.78M | -12.3% | -5.5% | 82.6% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
BDMDBaird Medical Investment Holdings Limited | FY2025 | $20.13M | +226.0% | +73.4% | 89.3% |
| LTM Jun 2026 | $9.54M | +8.0% | +1.0% | 11.9% | |
MDAISpectral AI, Inc. | LTM Mar 2026 | $7.09M | -63.2% | — | 42.4% |
| LTM Mar 2026 | $6.76M | +14.7% | +31.0% | 30.0% | |
| Peer median (excluding SRTS) | $20.13M | -12.3% | +0.3% | 62.5% | |
Competitors are the stored peer set for SRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.04M | 44.53M | 24.41M | 41.81M | 27.48M |
| Cost of Revenue | 10.05M | 14.9M | 10.35M | 17.38M | 15.62M |
| Gross Profit | 16.99M | 29.63M | 14.06M | 24.43M | 11.87M |
| Gross Margin | 62.8% | 66.5% | 57.6% | 58.4% | 43.2% |
| Research & Development | 3.44M | 3.46M | 3.68M | 4.22M | 7.78M |
| Selling, General & Admin | 9.43M | 11.34M | 10.76M | 12.13M | 14.4M |
| Operating Expenses | 12.87M | 14.8M | 14.44M | 16.34M | 22.17M |
| Depreciation & Amortization | 613K | 509K | 461K | 432K | 386K |
| EBITDA | 4.73M | 28.5M | 1.11M | 9.45M | (9.24M) |
| EBITDA Margin | 17.5% | 64.0% | 4.6% | 22.6% | -33.6% |
| Operating Income | 4.12M | 14.83M | (382K) | 8.09M | (10.31M) |
| Operating Margin | 15.2% | 33.3% | -1.6% | 19.4% | -37.5% |
| Interest Income | 2K | 382K | 992K | 932K | 683K |
| Interest Expense | 1K | 2K | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 13.16M | 1.03M | 932K | 683K |
| Income Before Tax | 4.12M | 27.99M | 652K | 9.02M | (9.62M) |
| Pre-Tax Margin | 15.2% | 62.9% | 2.7% | 21.6% | -35.0% |
| Income Tax Expense | 0 | 3.75M | 167K | 2.38M | (1.91M) |
| Net Income | 4.12M | 24.24M | 485K | 6.65M | (7.72M) |
| Net Margin | 15.2% | 54.4% | 2.0% | 15.9% | -28.1% |
| EPS (Basic) | 0.25 | 1.47 | 0.03 | 0.41 | (0.47) |
| EPS (Diluted) | 0.25 | 1.46 | 0.03 | 0.41 | (0.47) |
| Weighted Avg Shares | 16.48M | 16.48M | 16.26M | 16.31M | 16.33M |
| Weighted Avg Shares (Diluted) | 16.5M | 16.62M | 16.27M | 16.36M | 16.33M |
Sensus Healthcare, Inc.
NASDAQ:SRTS
Intrinsic Alpha fair value
Locked
Current Price
$3.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.